Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1467-1479

  de la Torre Iglesias, Paloma Marina ^a   García Rodriguez, Juan José ^a   Torrado, Guillermo ^b   Torrado, Susana ^a   Torrado Santiago, Santiago ^a,c   Bolás Fernández, Francisco ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anthelmintic activity; Benzimidazole carbamates; In vitro dissolution; Pharmacokinetics; Redispersible microparticles; Trichinella spiralis

Indexed keywords

ATROPINE; CARBOXYMETHYLCELLULOSE; DRUG CARRIER; LOW SUBSTITUTED HYDROXYPROPYLCELLULOSE; MEBENDAZOLE; METRIFONATE; REDISPERSIBLE MICROPARTICLE; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT; CELLULOSE; HYDROXYPROPYLCELLULOSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHELMINTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEMATODE LIFE CYCLE STAGE; NONHUMAN; PARASITE CLEARANCE; PARASITE EXAMINATION; PARTICLE SIZE; TRICHINELLA SPIRALIS; TRICHINOSIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; LIFE CYCLE STAGE; ORAL DRUG ADMINISTRATION; SOLUBILITY; SURFACE PROPERTY; TRICHINELLOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; BIOLOGICAL AVAILABILITY; CELLULOSE; DISEASE MODELS, ANIMAL; LIFE CYCLE STAGES; MEBENDAZOLE; MICE; MICE, INBRED STRAINS; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES; TRICHINELLA SPIRALIS; TRICHINELLOSIS;

EID: 84908056425     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S65561     Document Type: Article

References (41)

1. Hemphill A, Müller J. Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. J Helminthol. 2009;83(2): 99-111.
2. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2-3): 141-159.
3. Sievens-Figueroa L, Bhakay A, Jerez-Rozo JI, et al. Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications. Int J Pharm. 2012;423(2):496-508.
4. Loh GOK, Tan YT, Peh KK. Hydrophilic polymer solubilization on norfloxacin solubility in preparation of solid dispersion. Powder Technology. 2014;256:462-469.
5. Onoue S, Sato H, Ogawa K, et al. Improved dissolution and pharmacokinetic behavior of cyclosporine. A using high-energy amorphous solid dispersion approach. Int J Pharm. 2010;399(1-2):94-101.
6. Lim SC, Paech MJ, Sunderland B, Liu Y. In vitro and in vivo evaluation of a sublingual fentanyl water formulation. Drug Des Devel Ther. 2013;7:317-324.
7. Dinunzio J C, Brough C, Hughey J R, Miller DA, Williams RO, McGinity JW. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol dispersing. Eur J Pharm Biopharm. 2010;74(2):340-351.
8. Usha AN, Mutalik S, Reddy MS, Ranjith AK, Kushtagi P, Udupa N. Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates. Eur J Pharm Biopharm. 2008;70(2): 674-683.
9. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharm Biopharm. 2010;39(4):256-262.
10. Molina-Berríos A, Campos-Estrada C, Lapier M, et al. Benznidazole prevents endothelial damage in an experimental model of Chagas disease. Acta Trop. 2013;127(1):6-13.
11. Matadamas-Martínez F, Nogueda-Torres B, Hernández-Campos A, et al. Analysis of the effect of a 2-(trifluoromethyl)-1H-benzimidazole derivative on Trichinella spiralis muscle larvae. Vet Parasitol. 2013; 194(2-4):193-207.
12. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm. 2004;272(1-2): 29-36.
13. Swanepoel E, Liebenberg W, Villiers MM. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur J Pharm Biopharm. 2003;55(3):345-349.
14. Cirri M, Maestrelli F, Mennini N, Mura P. Influence of the preparation method on the physical-chemical properties of ketoprofen-cyclodextrin-phosphatidylcholine ternary Systems. J Pharm Biomed Anal. 2009; 50(5):690-694.
15. Cirri M, Maestrelli F, Mennini N, Mura P. Physical-chemical characterization of binary and ternary systems of ketoprofen with cyclodextrins and phospholipids. J Pharm Biomed Anal. 2009;50(5):683-689.
16. Vo C L, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm. 2013;85(3 Pt B):799-813.
17. García-Rodríguez JJ, Torre-Iglesias, PM, Vegas-Sánchez MC, Torrado-Durán S, Bolás-Fernández F, Torrado-Santiago S. Changed crystallinity of mebendazole solid dispersion: Improved anthelmintic activity. Int J Pharm. 2011;403(1-2):23-28.
18. Torrado S, López M L, Torrado G, Bolás F, Torrado S, Cadórniga R. A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation. Int J Pharm. 1997;156:181-187.
19. Beinborn NA, Dua J, Wiederhold NP, Smyth HD, Williams RO, 3rd. Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur J Pharm Biopharm. 2012;81(3):600-608.
20. García JJ, Bolás F, Torrado JJ. Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm. 2003;250(2):351-358.
21. Wakelin D, Lloyd M. Accelerated expulsion of adult Trichinella spiralis in mice given lymphoid cells and serum from infected donors. Parasitology. 1976;72(3):307-315.
22. Cerdeira AM, Mazzotti M, Gander B. Formulation and drying of miconazole and itraconazole nanosuspensions. Int J Pharm. 2013; 443(1-2):209-220.
23. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm. 2007;66(3):334-347.
24. Jana S, Maji N, Nayak AK, Sen KK, Basu SK. Development of chitosan-based nanoparticles through inter-polymeric complexation for oral drug delivery. Carbohydr Polym. 2013;98(1):870-876.
25. De Villiers MM, Terblanche RJ, Liebenberg W, Swanepoel E, Dekker TG, Song M. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. J Pharm Biomed Anal. 2005;38(3): 435-441.
26. Mura P, Manderioli A, Bramanti G, Furlanetto S, Pinzauti S. Utilization of differential scanning calorimetry as a screening technique to determine the compatibility of ketoprofen with excipients. Int J Pharm. 1995;119:71-79.
27. Pani NR, Nath LK, Acharya S, Bhuniya B. Application of DSC, IST, and FTIR study in the compatibility testing of nateglinide with different pharmaceutical excipients. J Therm Anal Calorim. 2012;108(1): 219-226.
28. Damian F, Blaton N, Naessens L, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci. 2000;10(4):311-322.
29. Froehlich PE, Gasparotto FS. Mebendazol: identificação das formas polimórficas em diferentes matérias-primas e medicamentos (referência e genéricos) disponíveis no mercado nacional. [Mebendazole: identification of polymorphic forms in different raw materials and drugs (reference and generics) available domestically]. Rev Ciênc Farm Básica Apl. 2005;26(3):205-210. Portuguese.
30. Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur J Pharm Biopharm. 2013;83(1):87-94.
31. Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. Int J Pharm. 2011;417(1-2): 94-100.
32. Mura P, Bettinetti GP, Cirri M, Maestrelli F, Sorrenti M, Catenacci L. Solid-state characterization and dissolution properties of Naproxen-Arginine-Hydroxypropyl-β-cyclodextrin ternary system. Eur J Pharm Biopharm. 2005;59(1):99-106.
33. Chadha R, Bala M, Arora P, Jain DV, Pissurlenkar RRS, Coutinho EC. Valsartan inclusion by methyl-β-cyclodextrin: Thermodynamics, molecular modelling, Tween 80 effect and evaluation. Carbohydr Polym. 2014;103(15):300-309.
34. Krishnaiah YS, Veer RP, Dinesh KB, Satyanarayana V, Karthiekeyan RS, Bhaskar P. Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. J Control Release. 2003;88(1):95-103.
35. Zhang M, Li H, Lang B, et al. Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing. Eur J Pharm Biopharm. 2012;82(3):534-544.
36. Yang W, Johnston KP, Williams RO, 3rd. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm. 2010; 75(1):33-41.
37. Hess JA, Chandrasekar PH, Mortiere M, Molinari JA. Comparative Efficacy of Ketoconazole and Mebendazole in Experimental Trichinosis. Antimicrob Agents Chemother. 1986;30(6):953-954.
38. de-la-Rosa JL, Alvarez N, Gomez-Priego A. Study of the reproductive capacity of Trichinella spiralis recovered from experimentally infected mice under-dosed with albendazole or mebendazole. Trop Biomed. 2007;24(2):93-97.
39. Maki J, Yanagisawa T. Comparative efficacy of flubendazole and mebendazole on encysted larvae of Trichinella spiralis (USA strain) in the diaphragm of mice and rats. J Helminthol. 1988;62(1):35-39.
40. Zardi EM, Petrarca V, Pozio E, Uwechie V, Tamburrini A, Laghi V. A case from India of neurocysticercosis responsive to albendazole treatment. Parasite. 2000;7(1):54-56.
41. Yépez-Mulia L, Morales-Hurtado R, Viveros-Guzmán N, et al. Evaluation of albendazole prodrugs in experimental trichinellosis. Arch Med Res. 1999;30(5):368-374.